A2 Biotherapeutics has raised $80 million to run three experimental CAR-T programs for solid tumor cancers. The ...
Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...
Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...
Sutro scale-up, Pharma mergers, FDA warnings to Indian firms, new Egypt facility, and UPS acquires Frigo-Trans ...
Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.
H1 acquires Ribbon Health to expand doctor-patient connections. Ribbon serves about 25M patients yearly; H1 aims to reach ...
Transcarent acquires Accolade for $621M in cash deal led by CEO Glen Tullman, combining health navigation platforms.
French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...
Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver ...
Lonza’s Synaffix has secured two separate licensing deals with Boehringer Ingelheim and Japanese drugmaker ...
Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance's company. But Crown ...
RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...